Cargando…

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

CONTEXT: Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized. OBJECTIVE: To assess the incidence and characteristics of...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Filette, Jeroen, Jansen, Yanina, Schreuer, Max, Everaert, Hendrik, Velkeniers, Brigitte, Neyns, Bart, Bravenboer, Bert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095250/ https://www.ncbi.nlm.nih.gov/pubmed/27571185 http://dx.doi.org/10.1210/jc.2016-2300

Ejemplares similares

Pembrolizumab for the treatment of uveal melanoma: A case series
por: Jansen, Yanina Jeanne Leona, et al.
Publicado: (2020)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
por: Vermeulen, Sim, et al.
Publicado: (2021)

SUN-923 Combination Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma
por: de Filette, Jeroen M K, et al.
Publicado: (2020)

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
por: de Filette, Jeroen M K, et al.
Publicado: (2019)

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
por: Awada, Gil, et al.
Publicado: (2021)

Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
por: Sol, Bastiaan, et al.
Publicado: (2020)

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
por: Du Four, Stephanie, et al.
Publicado: (2018)

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
por: Schreuer, Max, et al.
Publicado: (2016)

Undetectable thyroglobulin makes (123)I whole-body scan and stimulated thyroglobulin obsolete in follow-up care of differentiated thyroid cancer: a retrospective study
por: Sol, Bastiaan, et al.
Publicado: (2021)

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
por: Wilgenhof, Sofie, et al.
Publicado: (2012)

Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms
por: de Filette, Jeroen M. K., et al.
Publicado: (2022)

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma
por: Chevolet, Ines, et al.
Publicado: (2015)

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
por: Seremet, Teofila, et al.
Publicado: (2016)

Polyneuropathy in a young Belgian patient: A novel heterozygous mutation in the WNK1/HSN2 gene
por: de Filette, Jeroen, et al.
Publicado: (2016)

Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
por: Lambert, Ine, et al.
Publicado: (2021)

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)
por: Awada, Gil, et al.
Publicado: (2021)

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
por: Seremet, Teofila, et al.
Publicado: (2019)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
por: Schaefer, Anne, et al.
Publicado: (2020)

Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [(18)F]FDG PET/CT Imaging and Clinical Features
por: Dirks, Ine, et al.
Publicado: (2023)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse
por: Jansen, Yanina J. L., et al.
Publicado: (2021)

SAT-477 Melanoma Treated with Pembrolizumab Leading to Thyroiditis and Subsequent Hypothyroidism
por: Fishel, Heather
Publicado: (2020)

Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
por: Kurashige, Takashi, et al.
Publicado: (2021)

A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases
por: Van Bael, Kobe, et al.
Publicado: (2015)

Pituitary carcinoma - case series and review of the literature
por: Du Four, Stephanie, et al.
Publicado: (2022)

Development of destructive thyroiditis and diabetes mellitus after three injections of pembrolizumab for skin melanoma
por: Glibka, A. A., et al.
Publicado: (2021)

Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
por: Lima, Gian, et al.
Publicado: (2019)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

COVID-19 and Cushing’s disease in a patient with ACTH-secreting pituitary carcinoma
por: de Filette, J M K, et al.
Publicado: (2022)

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
por: Spalart, Valérie, et al.
Publicado: (2019)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

Fetal Microchimeric Cells in Blood of Women with an Autoimmune Thyroid Disease
por: Lepez, Trees, et al.
Publicado: (2011)

New developments in the management of advanced melanoma – role of pembrolizumab
por: Improta, Giuseppina, et al.
Publicado: (2015)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
por: Abdul-Karim, Raghad M, et al.
Publicado: (2017)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma
por: Ferguson, Ian, et al.
Publicado: (2019)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lnla71h8rqchkbcjmlriin8jeo